secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0000950170-24-066571
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA selects Larimar's nomlabofusp for START pilot program to accelerate FA development
--------------------------------------------------------------------------------

- FDA selects nomlabofusp for START pilot program based on potential clinical benefit and program readiness.
- Nomlabofusp is one of three CDER programs selected; BLA submission target remains 2H 2025.
- START program offers enhanced ad-hoc FDA communication to expedite pivotal studies and BLA preparation.
- Interim data from ongoing open-label extension study expected in Q4 2024.
- Nomlabofusp aims to increase frataxin levels, addressing root cause of Friedreich's ataxia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024066571/0000950170-24-066571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024066571/lrmr-20240530.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-066571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer